Abstract
Recent studies of venlafaxine [Wyeth Ayerst], one of the new dual-acting antidepressants, have indicated that the drug has a low risk of interactions with drugs that are substrates for the cytochrome P450 3A4 (CYP3A4) and 1A2 (CYP1A2) isoenzyme pathways. These studies were prompted by the US FDA’s concern regarding the adverse consequences of drug interactions with the CYP3A4 substrate terfenadine. The results of the venlafaxine studies were presented at the 98th meeting of the American Society for Clinical Pharmacology and Therapeutics [San Diego, California, March 1997].
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
